Relationship between ERCC1 expression and sensitivity of platinum-based chemotherapy in NSCLC: a systematic review

Abstract

Abstract: AIM: To evaluate the relationship between the expression of excision repair cross-complement 1 (ERCC1) gene and platinum-based chemotherapy sensitivity in non-small cell lung cancer. METHODS: Database including Medline (1991.1-2009.12), Pubmed, CBMDisc were searched and randomized clinical trials as well as retrospective case studies were collected. Meta analysis was executed using RevMan 4.2 software. RESULTS: One randomized controlled trial (RCT) and nine case reports were identified and anlyzed. The results of nine case reports indicated that the response rate of ERCC1-negative patients to platinum-based chemotherapy was obviously higher than that of ERCC1-positive patients(P=0.02). One retrospective research reported longer time to progression (TTP) (P<0.05) and two reported longer overall survival in ERCC1-negative patients (P<0.05) compared with those ERCC1-positive patients. The results of RCT indicated that adjuvant chemotherapy significantly prolonged survival among low ERCC1 expression patients compared with observation but not among patients with high ERCC1 expression. Better adjuvant regimen for high ERCC1 patients is needed.CONCLUSION: Low ERCC1 expression patients are benefit from platinum-based chemotherapy, but patients with high ERCC1 expression are not sensitive to platinum-based chemotherapy. ERCC1 is a useful biomarker to clinically predict the efficacy of adjuvant chemotherapy in NSCLC.

Key words: Non-small cell lung cancer (NSCLC), Excision repair cross-complement 1 (ERCC1), Chemotherapy sensitivity, Platinum drugs

CLC Number:

R969

XU Feng-hua, GUO Rong-rong, LI Xin, LONG Li-yan, ZHANG Gui-yun. Relationship between ERCC1 expression and sensitivity of platinum-based chemotherapy in NSCLC: a systematic review[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(1): 45-50.

References

[1] 中国抗癌协会肺癌专业委员会,编著.2007中国肺癌临床指南[M].北京:人民卫生出版社,2007.
[2] Siddik ZH.Cisplatin: mode of cytotoxic action and molecular basis of resistance[J]. Oncogene, 2003, 22(47): 7265-7279.
[3] Su D, Ma S, Liu P, et al.Genetic polymorphisms and treatment response in advanced non small cell lung cancer[J]. Lung Cancer, 2007, 56(2): 281-288.
[4] Rosell R, Taron M, Barnadas A, et al.Nucleotide excision repair pathways involved in cisplatin resistance in non small cell lung cancer[J]. Cancer Control, 2003, 10(4): 297-305.
[5] 黄培钰,张力,梁小曼,等.晚期非小细胞肺癌组织中ERCC,Metallothione,p53表达与铂类耐药性及预后的相关分析[J]. 癌症, 2004, 23(7): 840-845.
[6] 宁瑞玲, 宋向群, 罗元, 等. ERCC1、MT、P53和Bcl2 表达与含铂方案治疗晚期NSCLC 的关系研究[J].2006, 9(4): 373-375.
[7] 肖永营, 宋勇, 施毅, 等.非小细胞肺癌患者ERCC1蛋白表达与铂类标准方案化疗敏感性的关系研究[J]. 临床肿瘤学杂志,2007, 12(5): 339-342.
[8] 袁蕾蕾,王秀问. ERCC-1在晚期非小细胞肺癌中的表达及其与铂类药物化疗敏感性关系[J]. 华北煤炭医学院学报, 2007, 9(5): 605-607.
[9] 单利,韩志刚,刘莉,等. 晚期非小细胞肺癌ERCC1和BRCA1的表达及与顺铂耐药性的临床研究[J]. 肿瘤, 2009, 29(6): 571-574.
[10] Booton R, Ward T, Ashcroft L, et al.ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer[J]. J Thorac Oncol, 2007, 2(10): 902-906.
[11] Lord RV, Brabender J, Gandara D, et al.Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer[J]. Clin Cancer Res, 2002, 8(7): 2286-2291.
[12] Lee HW, Choi YW, Han JH, et al.Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy[J]. Lung Cancer, 2009, 65(3): 377-382.
[13] Ikeda S, Takabe K, Suzuki K.Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer[J]. Pathol Int, 2009, 59(12): 863-867.
[14] Olaussen KA, Dunant A, Fouret P, et al.DNA repair by ERCC1 in Non-Small-Cell Lung Cancer and Cidplatin-Based Adjuvant Chemotherapy[J]. N Engl J Med, 2006, 355(10): 983-991.
[15] Simon GR, Sharma S, Cantor A, et al.ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer[J]. Chest, 2005, 127(3): 978-983.
[16] Cobo M, Isla D, Massuti B, et al.Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer[J]. J Clin Oncol, 2007, 25(19): 2747-2754.